Several tyrosine kinase inhibitors are under investigation and have been applied clinically in ovarian cancer, particularly those targeting vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). This evidence concerns the gene KDR and ovarian carcinoma.